Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISOPHROL vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Relief of symptoms of seasonal or perennial allergic rhinitis,Relief of symptoms of vasomotor rhinitis,Relief of nasal congestion associated with the common cold,Relief of sinusitis symptoms
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Dexbrompheniramine is metabolized in the liver primarily via CYP450 enzymes; pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Approximately 50-60% bound to plasma proteins, primarily albumin.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
Volume of distribution is approximately 1.5-2.5 L/kg, indicating extensive tissue distribution.
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral bioavailability is about 70-80% due to first-pass metabolism.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
GFR 30-50 m L/min: administer every 6-8 hours. GFR 15-29 m L/min: administer every 12 hours. GFR <15 m L/min: not recommended.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution, reduce dose frequency. Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 6-11 years: 1/2 tablet (3 mg dexbrompheniramine / 30 mg pseudoephedrine) orally every 4-6 hours, max 2 tablets per day. Children <6 years: not recommended.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Initiate with 1/2 tablet every 6-8 hours; monitor for anticholinergic effects and hypertension; avoid in patients >65 years due to increased risk of adverse effects.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None.
None.
Cardiovascular effects: may cause hypertension, palpitations, arrhythmias,Central nervous system stimulation: may cause insomnia, dizziness, tremor,Urinary retention: use with caution in patients with BPH or urinary obstruction,Increased intraocular pressure: avoid in narrow-angle glaucoma,Elderly patients: more sensitive to anticholinergic and cardiovascular effects
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe hypertension,Coronary artery disease,Concurrent use of MAO inhibitors or within 14 days of such therapy,Narrow-angle glaucoma,Urinary retention,Severe renal impairment,Hypersensitivity to any component
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid consuming alcohol while taking Disophrol. Caffeine may increase restlessness and insomnia. There is no specific food interaction, but taking with food may reduce gastrointestinal upset.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis with antihistamine use, but data are limited; pseudoephedrine may be associated with a small risk of gastroschisis and hemifacial microsomia. Second and third trimesters: No specific fetal risks have been clearly established; pseudoephedrine may cause fetal tachycardia and decreased uterine blood flow at high doses. Avoid in third trimester due to potential for uterine contraction inhibition and neonatal respiratory depression from antihistamines.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
DISOPHROL is excreted into breast milk. Dexchlorpheniramine: Present in low levels, M/P ratio not established; may cause irritability and drowsiness in infants. Pseudoephedrine: Excreted into breast milk with M/P ratio of approximately 2.6-3.5; may cause infant irritability and decreased milk production. Use caution and monitor infant for excessive drowsiness or irritability.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustments are recommended in pregnancy; however, use lowest effective dose and shortest duration. Due to increased plasma volume and renal clearance in pregnancy, pseudoephedrine may have reduced efficacy; dose may need empirical adjustment based on response. Avoid extended-release formulations in pregnancy.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Disophrol combines an antihistamine (dexbrompheniramine) and a decongestant (pseudoephedrine). Avoid in patients with hypertension, coronary artery disease, or hyperthyroidism due to pseudoephedrine's sympathomimetic effects. Monitor for anticholinergic side effects (drowsiness, dry mouth) from the antihistamine component. Use with caution in glaucoma, urinary retention, and prostatic hypertrophy.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Take this medication as prescribed; do not exceed recommended dose due to risk of serious side effects.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Do not take with other medications containing decongestants or antihistamines.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or difficulty urinating.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISOPHROL vs ACTIFED, answered by our medical review team.
DISOPHROL is a Antihistamine/Decongestant Combination that works by Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISOPHROL and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISOPHROL is: 1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISOPHROL and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISOPHROL is classified as Category C. DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis wi. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.